JP2025502061A5 - - Google Patents
Info
- Publication number
- JP2025502061A5 JP2025502061A5 JP2024540882A JP2024540882A JP2025502061A5 JP 2025502061 A5 JP2025502061 A5 JP 2025502061A5 JP 2024540882 A JP2024540882 A JP 2024540882A JP 2024540882 A JP2024540882 A JP 2024540882A JP 2025502061 A5 JP2025502061 A5 JP 2025502061A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263297333P | 2022-01-07 | 2022-01-07 | |
| US63/297,333 | 2022-01-07 | ||
| US202263342542P | 2022-05-16 | 2022-05-16 | |
| US63/342,542 | 2022-05-16 | ||
| US202263394483P | 2022-08-02 | 2022-08-02 | |
| US63/394,483 | 2022-08-02 | ||
| US202263421541P | 2022-11-01 | 2022-11-01 | |
| US63/421,541 | 2022-11-01 | ||
| PCT/US2023/010326 WO2023133280A1 (en) | 2022-01-07 | 2023-01-06 | Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025502061A JP2025502061A (ja) | 2025-01-24 |
| JPWO2023133280A5 JPWO2023133280A5 (https=) | 2026-01-13 |
| JP2025502061A5 true JP2025502061A5 (https=) | 2026-01-13 |
Family
ID=85199214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024540882A Pending JP2025502061A (ja) | 2022-01-07 | 2023-01-06 | 再発性卵巣癌を、二重特異性抗ｍｕｃ１６×抗ｃｄ３抗体単独で、または抗ｐｄ－１抗体と組み合わせて治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230312718A1 (https=) |
| EP (1) | EP4460520A1 (https=) |
| JP (1) | JP2025502061A (https=) |
| KR (1) | KR20240130137A (https=) |
| AU (1) | AU2023204751A1 (https=) |
| CA (1) | CA3242629A1 (https=) |
| IL (1) | IL313864A (https=) |
| MX (1) | MX2024008055A (https=) |
| WO (1) | WO2023133280A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY194596A (en) * | 2016-09-23 | 2022-12-06 | Regeneron Pharma | Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates |
| TW202542187A (zh) * | 2023-12-12 | 2025-11-01 | 美商再生元醫藥公司 | 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| JP6240600B2 (ja) | 2011-07-24 | 2017-11-29 | キュアテク リミテッド | ヒト化免疫モノクローナル抗体の変異体 |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| MY194596A (en) | 2016-09-23 | 2022-12-06 | Regeneron Pharma | Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates |
| TW202504917A (zh) * | 2018-06-21 | 2025-02-01 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法 |
-
2023
- 2023-01-06 KR KR1020247026382A patent/KR20240130137A/ko active Pending
- 2023-01-06 MX MX2024008055A patent/MX2024008055A/es unknown
- 2023-01-06 IL IL313864A patent/IL313864A/en unknown
- 2023-01-06 JP JP2024540882A patent/JP2025502061A/ja active Pending
- 2023-01-06 CA CA3242629A patent/CA3242629A1/en active Pending
- 2023-01-06 US US18/094,176 patent/US20230312718A1/en active Pending
- 2023-01-06 AU AU2023204751A patent/AU2023204751A1/en active Pending
- 2023-01-06 EP EP23703960.7A patent/EP4460520A1/en active Pending
- 2023-01-06 WO PCT/US2023/010326 patent/WO2023133280A1/en not_active Ceased